白细胞介素-6表达在I期卵巢透明细胞癌中的预后影响
该回顾性队列研究纳入单机构192例I期卵巢透明细胞癌患者,中位随访91个月,估算5年总生存率为88.9%。多因素分析显示亚期分类和IL-6表达状态与较差总生存相关(p=0.010和p=0.027)。作者认为两者可能为独立预后因素,IL-6分子分层对优化早期卵巢透明细胞癌治疗策略可能至关重要。
要点
- I期卵巢透明细胞癌患者估算5年总生存率为88.9%,中位随访91个月。
- 多因素分析显示亚期分类和IL-6表达状态与较差总生存相关(p=0.010和p=0.027)。
- ARID1A表达缺失对生存无影响,但与亚期(p=0.001)、包膜破裂状态(p=0.011)和腹水细胞学(p=0.016)相关。
核心结论
- 亚期分类和IL-6表达状态可能均为I期卵巢透明细胞癌的独立预后因素。
- IL-6分子分层对优化早期卵巢透明细胞癌治疗策略以改善生存可能至关重要。
研究设计与样本
- 回顾性队列研究,纳入单机构治疗的192例I期卵巢透明细胞癌患者。
- 计算总生存期,分析包括卵巢透明细胞癌独特多样组织学特征在内的12项临床病理参数。
主要发现
- 所有I期卵巢透明细胞癌患者估算5年总生存率为88.9%,中位随访91个月。
- 多因素分析显示亚期分类与较差总生存相关(p=0.010)。
- 多因素分析显示IL-6表达状态与较差总生存相关(p=0.027)。
- ARID1A表达缺失对生存无影响,但与亚期(p=0.001)、包膜破裂状态(p=0.011)和腹水细胞学(p=0.016)相关。
- ARID1A与IL-6表达之间未发现明确关联;包括子宫内膜异位症、腺纤维瘤、结构模式和肿瘤细胞类型在内的组织学表现无预后影响。
临床怎么用
- 作者认为IL-6分子分层对优化早期卵巢透明细胞癌治疗策略以改善生存可能至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ovarian clear cell carcinoma (OCCC) frequently presents at an early stage. In stage I OCCC, the prognosis differs according to substage. In particular, predictive biomarkers and new treatment strategies are needed for stage IC2/IC3 disease. We investigated tumor biology and prognostic factors for stage I OCCC from a clinicopathological perspective, including the expression of ARID1A and IL-6, which are considered critical for OCCC carcinogenesis. METHODS: A retrospective cohort study of 192 patients with stage I OCCC treated at a single institution was performed. We calculated overall survival (OS) with respect to 12 clinicopathological parameters that included the unique and diverse histological features of OCCC. RESULTS: The estimated 5-year OS rate in patients with all stage I OCCC was 88.9% during a median of 91months of follow-up. The multivariate analysis indicated that substage classification and IL-6 expression status were associated with poor OS (p=0.010 and p=0.027, respectively). Loss of ARID1A expression had no impact on survival; however, it was associated with substage (p=0.001), capsule rupture status (p=0.011), and ascites cytology (p=0.016). No clear association was found between ARID1A and IL-6 expressions. Histological findings, including the presence of endometriosis, adenofibroma, architectural pattern, and tumor cell type, showed no prognostic effects. CONCLUSIONS: Both substage classification and IL-6 expression status may be independent prognostic factors in stage I OCCC. Therefore, IL-6 molecular stratification may be crucial in optimizing therapeutic strategies for early stage OCCC to improve survival.
引用
- Kawabata A, Yanaihara N, Nagata C, et al. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. Gynecol Oncol. 2017. PMID: 28673661. doi:10.1016/j.ygyno.2017.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。